Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shigehisa Kitano

Showing results (61-70 of 150) with videos related to

Pageof 15
Sort By:
Breast Cancer Research : BCR|March 21, 2023
Correction: Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironmentToru Hanamura, Shigehisa Kitano, Hiroshi Kagamu, et al.
JTO Clinical and Research Reports|October 14, 2021
Comparison of Tumor Microenvironments Between Primary Tumors and Brain Metastases in Patients With NSCLCDaiki Ikarashi, Tamio Okimoto, Takehito Shukuya, et al.
Breast Cancer (Tokyo, Japan)|February 29, 2020
Neutrophil-to-lymphocyte ratio and histological type might predict clinical responses to eriburin-based treatment in patients with metastatic breast cancerMayu Myojin, Yoshiya Horimoto, Mayuko Ito, et al.
Breast Cancer Research : BCR|February 1, 2023
Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironmentToru Hanamura, Shigehisa Kitano, Hiroshi Kagamu, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|August 4, 2009
Elevated fibrin-related markers in patients with malignant diseases suspected of having thrombotic disordersHideki Nomura, Hideo Wada, Toshiro Mizuno, et al.
Investigational New Drugs|May 1, 2025
An investigation of extended-interval dosing of atezolizumab in Japanese patients with advanced solid tumors: safety and pharmacokinetics of a dose of 1680 mg every 4 weeksShunsuke Kondo, Shigehisa Kitano, Jun Sato, et al.
Journal for Immunotherapy of Cancer|July 25, 2024
Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancersNoboru Yamamoto, Shigehisa Kitano, Takafumi Koyama, et al.
International Cancer Conference Journal|March 10, 2023
Myocarditis associated with immune-checkpoint inhibitors diagnosed by cardiac magnetic resonance imagingMasafumi Fukumitsu, Ryo Ariyasu, Mitsutomi Ishiyama, et al.
Cancer Chemotherapy and Pharmacology|November 4, 2020
Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignanciesShigehisa Kitano, Toshio Shimizu, Takafumi Koyama, et al.
Rheumatology (Oxford, England)|August 31, 2021
Chilblain lupus-like cutaneous reaction associated with systemic lupus erythematosus induced by immune checkpoint inhibitorKoichi Takeda, Kenji Nakano, Shohei Udagawa, et al.
Pageof 15

Showing results (61-70 of 150) with videos related to

Sort By:
Pageof 15
Breast Cancer Research : BCR|March 21, 2023
Correction: Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironmentToru Hanamura, Shigehisa Kitano, Hiroshi Kagamu, et al.
JTO Clinical and Research Reports|October 14, 2021
Comparison of Tumor Microenvironments Between Primary Tumors and Brain Metastases in Patients With NSCLCDaiki Ikarashi, Tamio Okimoto, Takehito Shukuya, et al.
Breast Cancer (Tokyo, Japan)|February 29, 2020
Neutrophil-to-lymphocyte ratio and histological type might predict clinical responses to eriburin-based treatment in patients with metastatic breast cancerMayu Myojin, Yoshiya Horimoto, Mayuko Ito, et al.
Breast Cancer Research : BCR|February 1, 2023
Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironmentToru Hanamura, Shigehisa Kitano, Hiroshi Kagamu, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|August 4, 2009
Elevated fibrin-related markers in patients with malignant diseases suspected of having thrombotic disordersHideki Nomura, Hideo Wada, Toshiro Mizuno, et al.
Investigational New Drugs|May 1, 2025
An investigation of extended-interval dosing of atezolizumab in Japanese patients with advanced solid tumors: safety and pharmacokinetics of a dose of 1680 mg every 4 weeksShunsuke Kondo, Shigehisa Kitano, Jun Sato, et al.
Journal for Immunotherapy of Cancer|July 25, 2024
Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancersNoboru Yamamoto, Shigehisa Kitano, Takafumi Koyama, et al.
International Cancer Conference Journal|March 10, 2023
Myocarditis associated with immune-checkpoint inhibitors diagnosed by cardiac magnetic resonance imagingMasafumi Fukumitsu, Ryo Ariyasu, Mitsutomi Ishiyama, et al.
Cancer Chemotherapy and Pharmacology|November 4, 2020
Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignanciesShigehisa Kitano, Toshio Shimizu, Takafumi Koyama, et al.
Rheumatology (Oxford, England)|August 31, 2021
Chilblain lupus-like cutaneous reaction associated with systemic lupus erythematosus induced by immune checkpoint inhibitorKoichi Takeda, Kenji Nakano, Shohei Udagawa, et al.
Pageof 15